CJC-1295 Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once daily (no DAC) or 2–3 times weekly (with DAC) Dose Range: No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly Cycle Length: 8–12 weeks on, 4 weeks off Timing: Before bed on empty stomach to amplify natural GH pulse during sleep
Reconstitution
Vial Size: 5mg Water Volume: 2.5mL Concentration: 2mg/mL
Titration Schedule
No DAC: Daily: 100 mcg SC before bed With DAC: 2–3x/week: 1–2 mg per injection
Timeline & Pharmacokinetics
Onset: 15–30 minutes (no DAC); 1–4 hours (with DAC) Peak Plasma: 30–60 minutes (no DAC); 2–10 hours (with DAC) Half-Life: ~30 minutes (no DAC); 6–8 days (with DAC due to albumin binding) Steady State: 2–4 weeks (no DAC daily dosing); 3–4 weeks (with DAC) Time to Results: 4–8 weeks for sleep/recovery; 8–12 weeks for body composition Washout: 1–2 weeks (no DAC); 4–6 weeks (with DAC)
Storage
Lyophilized: −20 °C (−4 °F) Reconstituted: 2–8 °C (35.6–46.4 °F) Shelf Life: 28 days
Injection Sites
Abdomen, Thigh
Safety & Contraindications
Safety: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Contraindications: Active malignancy or history of cancer (GH promotes cell proliferation); Pregnancy and breastfeeding; Pituitary tumors or prior pituitary surgery
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.